» Articles » PMID: 11786565

Value of Positron Emission Tomography with [F-18]fluorodeoxyglucose in Patients with Colorectal Liver Metastases: a Prospective Study

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2002 Jan 12
PMID 11786565
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To assess prospectively the value of fluor-18-deoxyglucose (FDG) positron emission tomography (PET), in addition to conventional diagnostic methods (CDM), as a staging modality in candidates for resection of colorectal liver metastases.

Patients And Methods: In 51 patients analyzed for resection of colorectal liver metastases, clinical management decisions were recorded after a complete work-up with CDM. Afterward, FDG-PET scans were performed and any change of clinical management according to FDG-PET results was carefully documented. Discordances between FDG-PET and CDM results were identified and related to the final diagnosis by histopathology, intraoperative findings, and follow-up.

Results: In 10 (20%) out of 51 patients, clinical management decisions based on CDM were changed after FDG-PET findings were known. FDG-PET detected unresectable pulmonary (n = 5) and hepatic metastases (n = 1) and ruled out extrahepatic (n = 2) and hepatic disease (n = 2). Due to FDG-PET, eight patients were spared unwarranted liver resection or laparotomy and two other patients were identified as candidates for liver resection. When the results of FDG-PET were regarded as decisive in a retrospective analysis, potential change of management was 29% (15 patients). FDG-PET and CDM showed discordant extrahepatic results in 11 patients (22%) and discordant hepatic results in eight patients (16%). Compared with CDM, FDG-PET resulted in true upstaging (n = 11), true downstaging (n = 5), false upstaging (n = 1), and false downstaging (n = 2). The detection rate of liver metastases on a lesion basis was generally better for computed tomography than for FDG-PET (80% v 65%); this was related to tumor size.

Conclusion: FDG-PET as a complementary staging method improves the therapeutic management of patients with colorectal liver metastases, especially by detecting unsuspected extrahepatic disease.

Citing Articles

Colon cancer: the 2023 Korean clinical practice guidelines for diagnosis and treatment.

Ryu H, Kim H, Ji W, Kim B, Kim J, Moon S Ann Coloproctol. 2024; 40(2):89-113.

PMID: 38712437 PMC: 11082542. DOI: 10.3393/ac.2024.00059.0008.


Imaging Considerations before and after Liver-Directed Locoregional Treatments for Metastatic Colorectal Cancer.

Chlorogiannis D, Moussa A, Zhao K, Alexander E, Sofocleous C, Sotirchos V Diagnostics (Basel). 2024; 14(7).

PMID: 38611685 PMC: 11011364. DOI: 10.3390/diagnostics14070772.


PET/CT in assessment of colorectal liver metastases: a comprehensive review with emphasis on F-FDG.

Zirakchian Zadeh M Clin Exp Metastasis. 2023; 40(6):465-491.

PMID: 37682423 DOI: 10.1007/s10585-023-10231-9.


Prospective evaluation of F-FDG positron emission tomography in the preoperative staging of patients with hepatic colorectal metastases.

Akhurst T, Gonen M, Baser R, Schwartz L, Tuorto S, Brody L Hepatobiliary Surg Nutr. 2022; 11(4):539-554.

PMID: 36016741 PMC: 9396102. DOI: 10.21037/hbsn-19-357.


Challenges and opportunities in the development of metal-based anticancer theranostic agents.

Vaidya S, Gadre S, Kamisetti R, Patra M Biosci Rep. 2022; 42(5).

PMID: 35420649 PMC: 9109461. DOI: 10.1042/BSR20212160.